NASHVILLE, Tenn., Sept. 23 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that Caldolor® (ibuprofen) Injection is gaining momentum and being approved for use in a growing number of medical facilities across the country. Several key U.S. hospitals, including Orlando Regional Medical Center, St. Elizabeth Healthcare in the Greater Cincinnati region and the Joseph M. Still Burn Centers, have added the product to their formularies for patient use. Designed primarily for use in the hospital setting, Caldolor is the first injectable product approved for use in the United States for the treatment of pain and fever.
Orlando Regional Medical Center (ORMC) is one of more than 230 institutions that have granted formulary approval since the drug's September 2009 launch. The 808-bed hospital serves as Central Florida's only Level One Trauma Center.
"Since the introduction of Caldolor at ORMC I have had the opportunity to use the product in a variety of patients, but most notably in my trauma patients," said Dr. John T. Promes, Director of Trauma Services and Associate Director for Surgical Education at Orlando Regional Medical Center. "Severe pain is difficult to treat, especially in patients with complex issues such as numerous fractures, impaired breathing from a collapsed lung and any number of other issues. Adding Caldolor to my practice has enabled me to decrease reliance on opioids and make patients more comfortable more quickly than with opioids alone. Getting patients moving around sooner can lead to faster recovery and decreased potential need for transfer to the intensive care unit. While opioids alone generally mask pain, adding Caldolor represents a new and multi-faceted approach to pain management, allowing me to treat pain at the source."
In clinical trials, using Caldolor as adjunct